Capricor Therapeutics, Inc. · NASDAQ:CAPR
Capricor Therapeutics — Technical Presentation (March 2016)
5 slides from Capricor Therapeutics's technical presentation, Mar 17, 2016
Slide 1: Exosomes Program Update
NASDAQ: CAPR Transformative Therapies from Bench to Bedside www.capricor.com Exosomes Program Update March 17, 2016
Slide 2: Forward-Looking Statements
2 Forward - Looking Statements This presentation contains forward - looking statements and information that are based on the beliefs of the management of Capricor Therapeutics, Inc . (Capricor) as well as assumptions made by and information currently available to Capricor . All statements other than
Slide 3: CAP-2003 (CDC Exosomes) Rabbit Keratitis Proof-of-Concept Study
3 CAP - 2003 (CDC Exosomes) Rabbit Keratitis Proof - of - Concept Study – 18 - animal, six - day study which compared CAP - 2003 to placebo for the treatment of ocular surface injury and inflammation as caused by induced keratoconjunctivitis . – Over three days, ocular wounds were created on one eye
Slide 4: CAP-2003 (CDC Exosomes) Demonstrated Dose-Dependent Improvement
4 CAP - 2003 (CDC Exosomes) Demonstrated Dose - Dependent Improvement – Histopathology was performed on eyes after third (final) day. Placebo CAP - 2003 (low - dose) CAP - 2003 (high - dose)
Slide 5: CAP-2003 (CDC Exosomes) Conclusions
5 CAP - 2003 (CDC Exosomes) Conclusions – The totality of the clinical and histological data in this rabbit keratitis proof - of - concept study suggests that CAP - 2003 is capable of improving several relevant clinical and histological endpoints, including: 1. corneal wound healing 2. o cular surfa
Capricor Therapeutics — Technical Presentation (March 2016) on 6ix